Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Revenue: 2024-2025

Historic Revenue for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to $39.8 million.

  • Day One Biopharmaceuticals' Revenue fell 57.56% to $39.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.7 million, marking a year-over-year change of. This contributed to the annual value of $131.2 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Revenue is $39.8 million, which was up 17.36% from $33.9 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Revenue registered a high of $93.8 million during Q3 2024, and its lowest value of $8.2 million during Q2 2024.
  • Moreover, its 2-year median value for Revenue was $32.3 million (2025), whereas its average is $39.3 million.
  • Examining YoY changes over the last 5 years, Day One Biopharmaceuticals' Revenue showed a top increase of 313.92% in 2025 and a maximum decrease of 57.56% in 2025.
  • Over the past 2 years, Day One Biopharmaceuticals' Revenue (Quarterly) stood at $29.2 million in 2024, then plummeted by 57.56% to $39.8 million in 2025.
  • Its Revenue stands at $39.8 million for Q3 2025, versus $33.9 million for Q2 2025 and $30.8 million for Q1 2025.